This is a request for a Core Grant to Enhance Neuroscience Transfer (CoGENT) from the New York State Psychiatric Institute. Ten qualifying Base Grants in the mood and anxiety disorders research area have been selected. These grants represent a diversity of expertise, technologies, and scientific approaches, ranging from basic to treatment studies. Included are studies involving neuroimaging, electrophysiology, genetic markers, study of CSF neurotransmitter metabolites and proteins, treatment of refractory patients, treatment of the elderly, and consideration of comorbid disorders and ecologically-valid research designs. The main goal of the proposed CoGENT is to link these technologies and diverse areas of expertise so that multiple studies can benefit. In particular, we are dedicated to neuroimaging, electrophysiology, applying modern neuroscience technologies such as advanced brain protein chemistry, and genetic marker analysis to treatment research. In so doing, we hope to be able to speed the effort toward placing our understanding of psychopathology and treatment on a firm neuroscience platform. The proposed CoGENT builds upon strengths accumulated during nearly two decades of funding through the Mental Health Clinical Research Center (MHCRC) program. Specifically, three cores that have proven both successful and invaluable from our MHCRC have been revised and are included in this proposal. They are the Laboratory and Technical Support (LTS) Core (formerly the Biological Studies Unit), the Centralized Normal Control Recruitment (CNCR) Core, and the Biostatistics, Data Management, and Networking (BDMN) Core. These three cores will support the ten Base Grants, provide common resources that will facilitate technology and knowledge transfer among scientists, and encourage the development of novel research studies and approaches.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Resource-Related Research Projects (R24)
Project #
5R24MH061274-04
Application #
6639160
Study Section
Special Emphasis Panel (ZMH1-BRB-S (02))
Program Officer
Meinecke, Douglas L
Project Start
2000-06-01
Project End
2005-04-30
Budget Start
2003-06-01
Budget End
2005-04-30
Support Year
4
Fiscal Year
2003
Total Cost
$496,906
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Evans, Suzette M; Bisaga, Adam (2009) Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcohol Clin Exp Res 33:19-30
Schechter, Dianne; Endicott, Jean; Nee, John (2007) Quality of life of 'normal'controls: association with lifetime history of mental illness. Psychiatry Res 152:45-54
Bisaga, Adam; Evans, Suzette M (2006) The acute effects of gabapentin in combination with alcohol in heavy drinkers. Drug Alcohol Depend 83:25-32
Schechter, Dianne; Lebovitch, Rochelle (2005) Normal controls are expensive to find: methods to improve cost-effectiveness of the screening evaluation. Psychiatry Res 136:69-78
Mathew, Sanjay J; Mao, Xiangling; Coplan, Jeremy D et al. (2004) Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study. Am J Psychiatry 161:1119-21
Bisaga, Adam; Evans, Suzette M (2004) Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology (Berl) 172:16-24
Ogden, R Todd (2003) Estimation of kinetic parameters in graphical analysis of PET imaging data. Stat Med 22:3557-68
Clark, W Crawford; Yang, Joseph C; Tsui, Siu Lun et al. (2002) Unidimensional pain rating scales: a multidimensional affect and pain survey (MAPS) analysis of what they really measure. Pain 98:241-7
Mathew, Sanjay J; Coplan, Jeremy D; Smith, Eric L P et al. (2002) Cerebrospinal fluid concentrations of biogenic amines and corticotropin-releasing factor in adolescent non-human primates as a function of the timing of adverse early rearing. Stress 5:185-93
Mathew, S J; Coplan, J D; Gorman, J M (2001) Management of treatment-refractory panic disorder. Psychopharmacol Bull 35:97-110